CYDY
CYDY clinical trials: CytoDyn Inc.
Every trial on ClinicalTrials.gov where CytoDyn Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 24
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CYDY on the catalyst calendar · CYDY registry changes
- Primary completion Not registeredNo phase registeredNCT07536815An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally...CytoDyn, Inc. · TNBCTemporarily not availableCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2NCT06699836CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenCytoDyn, Inc. · Metastatic Colorectal Cancer (mCRC)Active, not recruitingCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 16, 2020ActualPhase 2/Phase 3NCT02859961Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionCytoDyn, Inc. · HIVCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2021ActualPhase 2NCT04504942Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsCytoDyn, Inc. · Solid Tumor, AdultCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2022ActualPhase 2/Phase 3NCT02990858An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyCytoDyn, Inc. · Human Immunodeficiency Virus (HIV)TerminatedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2022ActualPhase 2/Phase 3NCT05271370An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyCytoDyn, Inc. · HIV-1-infectionTerminatedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2021ActualPhase 2NCT04347239Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19CytoDyn, Inc. · Coronavirus Disease 2019CompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2022ActualPhase 2NCT02355184An Extension of Protocol PRO 140_CD01 StudyCytoDyn, Inc. · HIVTerminatedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2020ActualPhase 2/Phase 3NCT03902522PRO 140 in Treatment-Experienced HIV-1 SubjectsCytoDyn, Inc. · HIV-1-infectionCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2022ActualPhase 1/Phase 2NCT03838367Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCCytoDyn, Inc. · Triple Negative Breast NeoplasmsTerminatedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT04313075A Compassionate Use Study of Leronlimab in Breast CancerCytoDyn, Inc. · Metastatic Triple-Negative Breast CarcinomaNo longer availableCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2021ActualPhase 2NCT04678830Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19CytoDyn, Inc. · Coronavirus Disease 2019CompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2021ActualPhase 2NCT02737306A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationCytoDyn, Inc. · Graft Vs Host DiseaseTerminatedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2015ActualPhase 2NCT02175680Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionCytoDyn, Inc. · HIVCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 27, 2023Sponsor estimatePhase 2NCT05730673Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal CancerCytoDyn, Inc. · CCR5WithdrawnCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2005ActualPhase 1NCT00110591Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersCytoDyn, Inc. · HIV InfectionsCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2021ActualPhase 2NCT04521114Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCytoDyn, Inc. · Nonalcoholic Steatohepatitis (NASH)CompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2020ActualPhase 2NCT04343651Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19CytoDyn, Inc. · Coronavirus Disease 2019CompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2018ActualPhase 2/Phase 3NCT02483078Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140CytoDyn, Inc. · HIVCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT02759042An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 StudyCytoDyn, Inc. · HIVNo longer availableCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2017Sponsor estimatePhase 2NCT01272258A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral...CytoDyn, Inc. · HIVWithdrawnCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2008ActualPhase 2NCT00613379PRO 140 by IV Administration in Adults With HIV-1 InfectionCytoDyn, Inc. · HIV InfectionsCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2008ActualPhase 2NCT00642707Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 InfectionCytoDyn, Inc. · HIV -1 InfectionCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualNo phase registeredNCT01048372Observational Study of Blood Treated With CytolinCytoDyn, Inc. · HIV InfectionsCompletedCYDYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2023Sponsor estimatePhase 3NCT04901689Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane OxygenationHospital Israelita Albert Einstein · COVID-19 PneumoniaSuspendedCYDYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner